Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4269947 | 0.98 | LMNA (0.50) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL994489 | 0.84 | MAPT (0.44) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL4624964 | 0.83 | — | — | |
| SCHEMBL8281891 | 0.82 | MAPT (0.61) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL30792604 | 0.76 | CYP3A4 (0.55) | RAB9AMAPTALDH1A1CA12CA1 | |
| SCHEMBL8022331 | 0.76 | CA1 (0.38) | SMN1; SMN2NPC1RAB9AGAAKDM4E | |
| SCHEMBL31152587 | 0.76 | AHR (0.40) | SMN1; SMN2NPC1RAB9AMAPTGAA | |
| SCHEMBL7938899 | 0.76 | MMP12 (0.40) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL9518303 | 0.76 | BLM (0.46) | LMNANPC1RAB9AMAPTCA12 | |
| SCHEMBL16211043 | 0.76 | KIF11 (0.40) | SMN1; SMN2NPC1RAB9AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10251827-B2 | Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst | L'OREAL (FR) | 2019-04-09 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| US-20160128922-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | L'OREAL (FR) | 2016-05-12 | — | — | US | disclosed |
| US-20160128922-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | L'OREAL (FR) | 2016-05-12 | — | — | US | disclosed |
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| EP-1773835-A2 | PYRIDO-PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF FOR TREATING CANCER | Sanofi-Aventis (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006016067-A2 | PYRIDO-PYRIDO PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF FOR TREATING CANCER | SANOFI-AVENTIS (FR) | 2006-02-16 | — | — | WO | disclosed |
| US-20040102489-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | SUGEN, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6649635-B2 | For therapy of cancer | SUGEN, INC. | 2003-11-18 | — | — | US | disclosed |
| EP-0915869-B1 | NOVEL TRICYCLIC N-CYANOIMINES USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORP (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020065283-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | MCMAHON GERALD (US) | 2002-05-30 | — | — | US | disclosed |
| US-6316479-B1 | ANTICANCER AGENTS | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-0645384-A1 | Azoxycyanobenzodioxane derivatives and their use as fungicides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1995-03-29 | — | — | EP | disclosed |
| US-4083844-A | Phenylazo orthocyano phenylazo or orthocyano phenylazo phenylazo containing dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | DPYD, PNPO, TYMP | LMNA 2522/4885SMN1; SMN2 1854/4885NPC1 1896/4885 |
| US-10251827-B2 | Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst | KRT18, CYB5R3, CBR3 | LMNA 716/4885SMN1; SMN2 3563/4885NPC1 4723/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LMNA 3015/4885SMN1; SMN2 882/4885NPC1 4398/4885 |
| US-20020065283-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | ABL1, ERBB2, PRKDC | LMNA 3694/4885SMN1; SMN2 2016/4885NPC1 2134/4885 |
| US-20040102489-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | ABL1, ERBB2, PRKDC | LMNA 3694/4885SMN1; SMN2 2016/4885NPC1 2134/4885 |
| US-20160128922-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | KRT18, CYB5R3, CBR3 | LMNA 799/4885SMN1; SMN2 3280/4885NPC1 4723/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LMNA 3115/4885SMN1; SMN2 986/4885NPC1 4434/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LMNA 3115/4885SMN1; SMN2 986/4885NPC1 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.